After 24 weeks of Dupilumab treatment, the analyzed patients experienced remarkable improvement in SNOT-22, NPS and NRS parameters; while resulted in a significant increase of peripheral eosinophilia and in the reduction of total IgE. Here, IGHE is linked to Increased total eosinophil count.